SAN DIEGO , Oct. 2, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced today that the company will be presenting at the 3 ^rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012 , at the New York Academy of Medicine in New York .

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO )

Punit Dhillon , President and CEO, will provide an overview of ImmunoPulse, a treatment that uses OncoSec's patented electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine.

The presentation is expected to begin at 9:15AM ET .

A live and archived webcast of the company's presentation at the conference hosted by MD Becker Partners LLC will be available at www.regonline.com/mdb2012 .